Diranersen

CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...

CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...